Ultragenyx Pharmaceutical RARE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$185M-22.5% | -$128.56M+3.5% | -$180.41M-35.1% | -$114.95M+12.6% | -$151M+11.5% | ||
| $8M-11.1% | $8.79M-7.9% | $8.61M-1.7% | $8.61M-2.9% | $9M+1.8% | ||
| -$197M-18.7% | -$99.83M-25.9% | -$91.42M-36.5% | -$108.75M-41.3% | -$166M+13.0% | ||
| $1M0.0% | $938K+475% | $1.28M-21.0% | $2.78M+38.6% | $1M-68.9% | ||
| -$49M-141% | —— | $117.18M+143% | $71.07M+17.3% | $120M+27.1% | ||
| -$247M-449% | $221.46M— | $26.06M+108% | $49.49M-86.5% | -$45M+53.6% | ||
| -$198M-18.6% | -$100.77M-26.8% | -$92.7M-35.1% | -$111.53M-41.2% | -$167M+13.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ultragenyx Pharmaceutical generate?
- Ultragenyx Pharmaceutical (RARE) generated -$497.0M in operating cash flow over the trailing twelve months.
- What is Ultragenyx Pharmaceutical's free cash flow?
- After $6.0M of capital expenditures, Ultragenyx Pharmaceutical's free cash flow was -$503.0M over the trailing twelve months, down 27.6% year over year.
- Where does Ultragenyx Pharmaceutical's cash flow data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
